Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4JKM

Crystal Structure of Clostridium perfringens beta-glucuronidase

Summary for 4JKM
Entry DOI10.2210/pdb4jkm/pdb
Related4JKK 4JKL
DescriptorBeta-glucuronidase, Maltose-binding periplasmic protein (3 entities in total)
Functional Keywordsalpha/beta barrel, beta-sandwich, sugar-binding domain, glycosyl hydrolase, hydrolase
Biological sourceClostridium perfringens
More
Cellular locationPeriplasm: P0AEX9
Total number of polymer chains4
Total formula weight226709.52
Authors
Wallace, B.D.,Redinbo, M.R. (deposition date: 2013-03-09, release date: 2014-09-17, Last modification date: 2024-02-28)
Primary citationWallace, B.D.,Roberts, A.B.,Pollet, R.M.,Ingle, J.D.,Biernat, K.A.,Pellock, S.J.,Venkatesh, M.K.,Guthrie, L.,O'Neal, S.K.,Robinson, S.J.,Dollinger, M.,Figueroa, E.,McShane, S.R.,Cohen, R.D.,Jin, J.,Frye, S.V.,Zamboni, W.C.,Pepe-Ranney, C.,Mani, S.,Kelly, L.,Redinbo, M.R.
Structure and Inhibition of Microbiome beta-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.
Chem.Biol., 22:1238-1249, 2015
Cited by
PubMed Abstract: The selective inhibition of bacterial β-glucuronidases was recently shown to alleviate drug-induced gastrointestinal toxicity in mice, including the damage caused by the widely used anticancer drug irinotecan. Here, we report crystal structures of representative β-glucuronidases from the Firmicutes Streptococcus agalactiae and Clostridium perfringens and the Proteobacterium Escherichia coli, and the characterization of a β-glucuronidase from the Bacteroidetes Bacteroides fragilis. While largely similar in structure, these enzymes exhibit marked differences in catalytic properties and propensities for inhibition, indicating that the microbiome maintains functional diversity in orthologous enzymes. Small changes in the structure of designed inhibitors can induce significant conformational changes in the β-glucuronidase active site. Finally, we establish that β-glucuronidase inhibition does not alter the serum pharmacokinetics of irinotecan or its metabolites in mice. Together, the data presented advance our in vitro and in vivo understanding of the microbial β-glucuronidases, a promising new set of targets for controlling drug-induced gastrointestinal toxicity.
PubMed: 26364932
DOI: 10.1016/j.chembiol.2015.08.005
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.263 Å)
Structure validation

236371

PDB entries from 2025-05-21

PDB statisticsPDBj update infoContact PDBjnumon